ImmuneOncia Therapeutics Inc. (424870)

Overview

ImmuneOncia Therapeutics Inc. is a dynamic biopharmaceutical company that specializes in the development of immunotherapies for cancer, founded in 2016 as a joint venture between South Korea's Yuhan Corporation and the U.S.-based Sorrento Therapeutics. The company is currently in the clinical stage of development, focusing on creating novel treatments aimed at improving outcomes for cancer patients globally. ImmuneOncia is particularly concentrated on antibody-based therapies, with a significant emphasis on immune checkpoint inhibitors, which play a vital role in enhancing the body's immune response against tumors. The company's headquarters is located in Yongin, South Korea, where it drives innovation in the biopharmaceutical sector and supports Korea's growing role in the global oncology market.

Among its notable achievements is the lead program IMC-001, a PD-L1 inhibitor that has gained recognition as the first domestically developed drug of its class to receive investigational new drug status in Korea. This landmark status is indicative of the company's robust research and development initiatives, as IMC-001 continues to advance through late-stage clinical trials. Furthermore, ImmuneOncia is actively expanding its pipeline with various monoclonal and bispecific antibodies, targeting key immune pathways that are critical in the fight against cancer.

Products and Services

• IMC-001 (PD-L1 Inhibitor)

  IMC-001 stands at the forefront of ImmuneOncia's therapeutic offerings as a PD-L1 inhibitor. This innovative drug is recognized as the first of its kind developed domestically in Korea to successfully achieve investigational new drug status. Currently undergoing late-stage clinical trials, IMC-001 aims to enhance the immune response against cancer cells by blocking the PD-L1 pathway, thereby activating T cells to better target and eliminate tumors.

• Monoclonal Antibodies

  ImmuneOncia is developing various monoclonal antibodies that target specific proteins involved in immune regulation. These treatments are designed to modulate the immune system's response to cancer more effectively, providing an opportunity to address diverse oncology indications. The monoclonal antibodies are part of a broader strategy to create personalized therapy options for patients.

• Bispecific Antibodies

  The company is at the forefront of innovation with next-generation bispecific antibodies including combinations such as PD-L1×CD47 and PD-L1×TIGIT. These bispecifics are engineered to engage two distinct targets simultaneously, enhancing the immune response while overcoming resistance mechanisms that tumors may utilize. As part of a strategic initiative, these bispecific antibodies aim to provide more effective treatment options for complex cancer scenarios.

• Research and Development

  ImmuneOncia is dedicated to continuous research and development efforts to discover and develop cutting-edge immunotherapies. The company focuses on addressing unmet needs within oncology, driving forward new therapies that can potentially transform the landscape of cancer treatment. With a commitment to innovation, ImmuneOncia aspires to be a key player in shaping the future of cancer care both in Asia and internationally.